Chesley Taft & Associates LLC Cuts Position in Edwards Lifesciences Co. (NYSE:EW)

Chesley Taft & Associates LLC reduced its holdings in Edwards Lifesciences Co. (NYSE:EW) by 1.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 28,834 shares of the medical research company’s stock after selling 420 shares during the period. Chesley Taft & Associates LLC’s holdings in Edwards Lifesciences were worth $2,135,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Ballentine Partners LLC raised its holdings in shares of Edwards Lifesciences by 17.3% during the fourth quarter. Ballentine Partners LLC now owns 5,484 shares of the medical research company’s stock valued at $406,000 after acquiring an additional 810 shares during the last quarter. Aurora Investment Managers LLC. acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth $200,000. Harbor Investment Advisory LLC boosted its stake in shares of Edwards Lifesciences by 8.8% during the 4th quarter. Harbor Investment Advisory LLC now owns 17,825 shares of the medical research company’s stock worth $1,320,000 after purchasing an additional 1,442 shares during the last quarter. MassMutual Private Wealth & Trust FSB increased its stake in shares of Edwards Lifesciences by 1.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 21,076 shares of the medical research company’s stock valued at $1,560,000 after acquiring an additional 256 shares during the last quarter. Finally, Purus Wealth Management LLC lifted its holdings in shares of Edwards Lifesciences by 10.9% during the 4th quarter. Purus Wealth Management LLC now owns 3,589 shares of the medical research company’s stock worth $266,000 after acquiring an additional 354 shares during the period. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on EW shares. Citigroup upped their price target on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Evercore ISI dropped their price target on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a research note on Tuesday, October 1st. Wolfe Research lowered Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price objective on the stock. in a research note on Thursday, January 16th. The Goldman Sachs Group increased their target price on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, December 5th. Finally, Truist Financial reaffirmed a “hold” rating and set a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $78.48.

Insider Activity at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 500 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the sale, the vice president now directly owns 23,189 shares in the company, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $3,077,593.52. This trade represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 33,000 shares of company stock worth $2,195,180 in the last 90 days. 1.27% of the stock is currently owned by company insiders.

Edwards Lifesciences Stock Down 0.1 %

Shares of NYSE:EW opened at $69.77 on Tuesday. The company’s fifty day moving average is $72.12 and its two-hundred day moving average is $71.03. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The stock has a market capitalization of $41.15 billion, a price-to-earnings ratio of 10.07, a price-to-earnings-growth ratio of 3.58 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting the consensus estimate of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The firm had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same quarter in the prior year, the business earned $0.59 earnings per share. Edwards Lifesciences’s quarterly revenue was up 8.9% on a year-over-year basis. Equities analysts anticipate that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.